

In Vitro Assay Models for Drug Safety and Efficacy Assessment

Daiichi Sankyo, a global pharmaceutical company, is seeking *in vitro* models to assess immune-mediated organ toxicity for drug safety, as well as advanced *in vitro* models to evaluate drug efficacy in breast and lung cancers.



Approaches of Interest:

- **Assessment of immune-mediated organ toxicity for drug safety**
 - *In vitro* models to evaluate immune-mediated organ toxicities caused by pharmaceutical compounds, such as immuno-oncology drugs, in humans
 - The ability to detect the risk potential of drug-induced immune-mediated organ toxicity in humans using appropriate endpoint evaluations and to justify the validity of those evaluations using clinical drugs
 - Evaluation models incorporating technologies such as Microphysiological Systems (MPS) or co-culture systems with immune cells are of interest, although a simpler and precise approach would be preferred
 - Models for all organs are of interest, with particular emphasis on vital systems including lung or heart
- ***In vitro* assay models for drug efficacy assessment**
 - Repeatable and quantitatively measurable *in vitro* assay models/systems using iPSC-derived cells and patient-derived organoids to assess drug efficacy for breast and lung cancers
 - Model should be validated using multiple existing drugs, and drug-resistant models are also of interest
 - Assay models incorporating technologies such as MPS and imaging analysis techniques are also of interest

Out of Scope:

- Single-use test systems for drug efficacy assessments

Developmental Stages of Interest:

- Basic research through to clinical development with promising and unique technologies is within scope

Submission Information

Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. **Our client is also open to novel research proposals which can be outlined using this [submission form](#).** In submitting to this campaign, you confirm that your submission contains only non-confidential information.

Opportunity for Collaboration

Our client is open to a range of collaboration opportunities, with the most appropriate outcome being decided on a case-by-case basis. Example outcomes include licensing assets, project/PhD funding, MTA, and research collaborations.

Opportunities sought

-  Technologies
-  Centres of excellence
-  Academics and expertise
-  Research projects
-  Biotech assets
-  Spinout companies

Submissions

Please submit relevant, non-confidential opportunities online [here](#)

Deadline: **5th January 2026 - 11:59 pm GMT**

Have any questions?

Contact our team at discover@in-part.co.uk